Attitudes among parents of persons with autism spectrum disorder towards information about genetic risk and future health

Jarle Johannessen1,2✉, Terje Nærland1,2, Sigrun Hope1,2, Tonje Torske3, Anett Kaale2,4, Katrine V. Wirgenes5, Eva Malt6,7, Srdjan Djurovic5,8, Marcella Rietschel9 and Ole A. Andreassen1,10,11

© The Author(s) 2021

Clinical relevance of genetic testing is increasing in autism spectrum disorder (ASD). Information about genetic risk may contribute to improved diagnostics, treatment and family planning, but may also be perceived as a burden. Knowledge about the families’ preferences with regard to genetic risk information is important for both health care professionals and policy makers. We investigated attitudes towards sharing information about genetic risk of ASD and knowledge about future health among parent members of the Norwegian Autism Association (N = 1455) using a questionnaire, and the relationships with parent and child characteristics, such as age, gender and ASD severity. Most preferred autonomy in deciding whom to inform about genetic risk of ASD (74.4%) and a minority supported extensive intra-familial disclosure of the genetic risk (41.1%). The majority agreed that it is an obligation to know as much as possible relevant for future health (58.0%) and only 51.7% agreed to a principle of a ‘right not to know’. In regression models, the attitudes were associated with opinions about benefits and harms of genetic testing (e.g., treatment, family planning, understanding of ASD pathology, insurance discrimination and family conflict). In sum, the findings show that most parents want to know as much as possible relevant for their children’s future health and keep their autonomy and intra-familial confidentiality about genetic risk information. Nearly half of the parents were not concerned with a “right not to know”. These attitudes can inform development of guidelines and bioethics in the age of genomic precision medicine.

European Journal of Human Genetics (2022) 30:1138–1146; https://doi.org/10.1038/s41431-021-00966-y

INTRODUCTION

Autism spectrum disorder (ASD) is defined by social communication and interaction deficits and repetitive behaviours. The global prevalence is about 1% and disease burden is high [1]. Heritability is estimated up to 90% [2]. Consistent with complex inheritance, both environmental risk factors and common gene variants with individually small effect size have been implicated in disease etiology [3, 4]. Rare variants or copy number variants, especially de novo variants, associated with a large risk of ASD are found in a minority of persons [5]. The relative contribution of rare and common variants has been estimated to 2.5–15% and 12–52%, respectively [6].

Genetic tests have shown little practical benefit for most people with ASD [5]. An ASD diagnosis is still based on descriptive and behavioural criteria [7]. The proportion of cases in which the etiology can be determined with genetic testing is expected to increase to 30–40%, and clinical use is expanding [8]. Clinical genetic testing may have potential to aid early identification, predict prognosis and guide interventions [9]. It may also trigger screening for medical problems, provide a medical explanation and help find specific support groups and assist family planning [5, 10].

 Genetic testing typically includes extensive counseling and emotional support. Still, the process of absorbing genetic risk information may be difficult for parents. Identity issues may arise, [11] genetic contributions may be overestimated and consequently the value of behavioural interventions could be downplayed [12]. Family planning may be influenced in form of discontinued reproduction [13] and issues of blame and guilt [14] may affect family relations [15]. Stigmatization [16], discrimination in employment and insurance [17] and negative general attitudes in society at large may also occur [18, 19]. For non-psychiatric disorders, no large negative, ethical, legal and social impacts (ELSI) of clinical genetic testing have been identified in the general population [20]. However, impacts may vary across traits investigated and of the test results [20, 21].

To reduce negative impact of genetic risk information a “right not to know” may be claimed. This right has support in various...
ethical and legal instruments, e.g., the European Convention on Human Rights and Biomedicine, UNESCO’s Universal Declaration on the Human Genome and Human Rights [22] and the World Health Organization’s Review of Ethical Issues in Medical Genetics from 2003. A “right not to know” may be in opposition to e.g., the ‘right to know’ and health care professionals’ obligation to inform, and these principles [23] are usually balanced on a case to case basis. Little is known about attitudes towards these principles in parents of children with ASD, making it difficult to develop empirically informed ethical guidelines on genetic testing and the return of genetic results in clinical practice [23].

In general psychiatry the majority of patients and parents have claimed full autonomy in receiving and sharing genetic risk information and full support of professional-patient confidentiality [24, 25]. In the present study we focus on genetic testing in ASD. Our aim was to explore parents’ attitudes towards four aspects: (i) Should parents decide whom to inform about genetic risk information? (ii) Should genetic risk information be shared extensively in the family? (iii) Do we have an obligation to obtain information? (iv) How important is a ‘right not to know’? We also investigated how the responses to these attitude questions were related to characteristics of parent (i.e., age and gender) and child (i.e., ASD severity and gender) relevant for clinical genetic testing and counseling. To make the findings relevant for practical bioethical guidelines, parents in favour and parents against clinical genetic testing for ASD were separated in the analyses. Finally, we explored the relation between parents’ attitudes and previously reported data on perceptions of benefits and harms of clinical genetic testing in children with ASD [26].

Based on previous findings in general psychiatry [24, 25, 27] we have four hypotheses: (#1) The majority of parents want to decide themselves whom to inform about genetic risk, independent of their child’s disease severity (Asperger syndrome vs. infantile autism); (#2) The majority of parents prefers no intra-familial disclosure of genetic risk; (#3) The majority of parents agree that everyone has an obligation to know as much as possible relevant information for future health of themselves and their children and that this opinion will be most wide-spread in parents of children with severe ASD; (#4) The majority of parents find a ‘right not to know’ about health information important, and this attitude is particularly prevalent among parents with children with milder ASD.

MATERIALS AND METHODS

Participants

In collaboration with the Norwegian Autism Association, all parent members were invited to participate. Those registered with email addresses were contacted by email, which included a link to a web-based questionnaire. Parents without a registered email address received the questionnaire by paper mail, which included a prepaid return envelope. Email but not paper mail reminders were sent to those not responding. Answers were anonymous. In total, 3539 invitations were sent (1990 by email and 1549 by paper mail) and 1455 parents responded (41%). Of those, 917 (63%) responded through the web and 538 (37%) by posting the questionnaire. Eleven responses were missing parents’ age, 7 were missing parents’ gender, 23 were missing children’s age, 29 were missing children’s gender and 39 were missing specific ASD diagnosis. No financial incentive or other rewards were provided to the respondents. The survey was open to responders from first half of 2014 and closed at the end of 2014 after two reminders.

Norwegian setting

This study was conducted in Norway where WHO’s International Classification of Diseases 10th revision (ICD-10) has been used since 1997. Norway has a public health and school system. Those with special needs have the right to individually tailored special education services. The most common intervention programs for individuals with ASD are applied behaviour analysis (ABA) or ABA derivatives, various forms of augmentative and alternative communication and the TEACCH method [28]. The public health care system provides genetic testing, centralized to medical genetics departments at the university hospitals. If genetic test is indicated, the first-tier diagnostic genetic test is array CGH (CNV screening) or specific mutation screening [3]. If the condition is complicated by intellectual disability or congenital malformations, exome sequencing with parental samples might be offered. When a CNV or rare variant is identified in a child with ASD, the family is offered genetic counseling and provided preclinical testing/Carrier testing of the parents.

Questionnaire

The questions concerning attitudes to genetic testing were part of a questionnaire with 45 items divided into four sections. The first section asked about age and gender of the parents. The second section asked about the parent’s firstborn child with an ASD diagnosis, the child’s specific ASD diagnosis (infantile autism or Asperger syndrome), age at diagnosis, comorbid somatic and psychiatric diagnoses and services offered and received from the specialist health care system. Parents were not asked how many children they have with ASD. The fourth section asked 23 questions about attitudes towards (i) genetic research, (ii) clinical genetic testing and (iii) receiving information on general health related information and ASD-specific genetic risk. The questionnaire emphasized that a predictive genetic test for ASD is currently not available, but asked participants to imagine the existence of a clinical test that could indicate the risk of ASD.

Eight questions were adapted from a survey of attitudes to genetic research and testing in families with a risk of malignant melanoma [9] and adjusted to the context of ASD. The remaining 15 questions were developed by our team and subsequently tested by representatives of the Autism Association Norway, guided by themes elicited in a qualitative study of awareness and attitudes among parents of children with ASD [19]. Overall psychometric properties of the questionnaire have not been formally established, but the development process involved a team of experts from multiple clinical disciplines and non-expert representatives from the advocacy organization. Thus, we consider face and content validity to be high. Responses were designed in a 5-point Likert format with the “alternatives” “strongly disagree”, “partly disagree”, “neither disagree nor agree”, “partly agree” and “strongly agree”, in addition to “Don’t know” and “I don’t have an opinion”. We estimated 10–15 min time to complete the questionnaire.

The results regarding attitudes towards (i) genetic research and (ii) clinical genetic testing have been reported previously [26, 29]. Attitudes towards (iii) information about future health and genetic risk of ASD were addressed in four items and reported here. The collected information was anonymous and the Regional Committee for Medical and Health Research Ethics (REC) concluded that the study did not require REC approval.

Data handling and analyses

Stata version 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC) was used for descriptive statistics and IBM SPSS version 27 was used for t tests and regression analyses. The responses from the questionnaire received by post were scanned and read using ABBYY FlexiCapture 10 (ABBYY Europe, Munich, Germany) and imported into an SPSS file. The online responses were imported directly.

First, descriptive statistics was performed. We treated the attitude variables as interval data and used t tests to compare the attitudes of (a) mothers versus fathers, (b) parents of children with infantile autism versus parents of children with Asperger syndrome and (c) parents in favour of versus parents against clinical genetic testing [30]. To investigate how parents’ attitudes to benefits and harms of genetic testing influence their attitudes to statements about receiving information relevant for future health and sharing ASD-specific genetic risk information, regression analyses with forward stepwise variable selection were performed. To ensure an empirically guided analysis, each step of the regression analyses was examined in order to identify sets of variables that in combination may represent sets associated with the reported attitude [31]. Due to lack of previous empirical knowledge about attitudes towards genetic testing among parents of children with ASD and a need to reduce model size, a forward stepwise procedure was chosen. Selection criterion for inclusion of variables in the model was p < 0.05. The final model selection was evaluated with the Automatic Linear Modelling procedure in SPSS to search the entire space of all possible models for best subset modelling [32]. Akaike’s Information Criterion Corrected (AICc) was used as selection criterion to prevent overfitting [32].
RESULTS
Sample description
Demographic and diagnostic characteristics of the responding parents and their children with ASD are shown in Table 1.

Attitudes toward sharing genetic risk information and towards knowing about future health
As seen in Tables 2, 74.4% of the parents agreed to the statement “parents should decide whom to inform about genetic risk for ASD” and 41.1% agreed to “inform as many as possible”. A total of 58.0% of the parents agreed to “obligation to know” and 51.7% agreed to “right not to know”.

Significantly more parents of children with infantile autism agreed to the statement “inform as many as possible” in comparison to parents of children with Asperger syndrome (t(1068) = 2.820, p < 0.05). The effect of disease severity is however small. Both means falls between “neither disagree nor agree” and “partly agree”. This disease severity association was still present after controlling for each step of the analyses are found in Table 4A. Reports of the sets together with the selected variable associated with the outcome variable are found in Table 4B together with the best model from an all-possible-subset approach.

Parents should decide whom to share genetic risk information with
In an all-possible-subsets approach of the attitude to the normativity of parental autonomy (“parents should decide”), the model with the smallest information loss was comprised of eight of the 11 predictors with varying relative variable importance (RVI) in the model: “insurance discrimination” (RVI = 0.274), “understand ASD” (RVI = 0.213), “improve planning” (RVI = 0.150), “socially constructed” (RVI = 0.145), “family planning” (RVI = 0.080) “family conflict” (RVI = 0.066), and “treatment relevant” (RVI = 0.037) and increased concern (RVI = 0.035); p range from <0.001 to 0.036; adj R² = 0.143, p < 0.001. A forward stepwise regression analysis of “parents should decide” produced a final model with the same variables except from “increased concern” (p range from <0.001 to 0.043; adj R² = 0.155, p < 0.001).

Share genetic risk information with as many as possible in the family
A best subset regression analysis of the attitude to the importance of full intra-familial disclosure (“inform as many as possible”) produced a model composed of “improve planning” (RVI = 0.451), “family planning” (RVI = 0.349), “recurrence prevention” (RVI = 0.140), “explain cause” (RVI = 0.045) and “family conflict” (RVI = 0.014); p range from <0.001 to 0.077; adj R² = 0.305, p < 0.001. A forward stepwise analysis of “important to inform as many as possible” included the same variables in the final model except from “family conflict” (p range from <0.001 to 0.010; adj R² = 0.319, p < 0.001).

Obligation to know
In a best subset regression analysis of the attitude to the normativity of being informed (“obligation to know”) nine of the eleven predictor variables was included, the most important being “improve planning” (RVI = 0.379), “family planning” (RVI = 0.255), “understand ASD” (RVI = 0.088), “family conflict” (RVI = 0.087) and “future treatment” (RVI = 0.065) and “recurrence prevention” (RVI = 0.047); p range from <0.001 to 0.142; adj R² = 0.190, p < 0.001. For all predictors, see Table 4B. In a forward stepwise analysis of “obligation to know” the same variables presented from the best subset model were included in the final stepwise model (p range from <0.001 to 0.045; R² = 0.206, p < 0.001).

A “right not to know”
In a best subset regression analysis of the attitude to the importance of a right to ignorance (“right not to know”) “insurance discrimination” (RVI = 0.350), “family conflict” (RVI = 0.263), “increased concern” (RVI = 0.229), “future treatment” (RVI = 0.086) and “family planning” (RVI = 0.071) were included (p range from <0.001 to 0.035; adj R² = 0.078, p < 0.001). In a forward stepwise analysis of “right not to know”, the same variables except “family planning” were included in the final model (p range from <0.001 to 0.038; R² = 0.085, p < 0.001).

DISCUSSION
The main findings of the present study were that a majority of the parents perceive it an obligation to obtain as much information as possible about their own and their children’s future health, and that they want autonomy and intra-familial confidentiality about genetic risk information. Interestingly, only a small majority agreed that a “right not to know” is important. These findings could be used to inform future guidelines about procedures for information about genetic testing in ASD.

In support of our hypothesis #1, a main finding was that 74.4% of the respondents agreed that parents themselves should decide

Table 1. Demographics of parents and their children with ASD.

| Responding parents n = 1455 |
|----------------------------|
| Age of parents: mean (SD) (range) | 46.7 (8.6) (22–87) |
| Gender of parents, females | 81% |
| Age of children with ASD: mean (SD) (range) | 16.5 (7.6) (3–58) |
| Gender of the children with ASD, males | 80.5% |
| Specific ASD diagnoses of the children | |
| Asperger syndrome | 49.4% |
| Infantile autism | 37.6% |
| Other ASD (Atypical autism and PDD-NOS) | 13.0% |

ASD Autism spectrum disorder, SD standard deviation, PDD-NOS Pervasive Developmental Disorder-Not Otherwise Specified.
whom to inform about a genetic risk of ASD. This attitude was independent of their child’s type of ASD diagnosis. The all-possible-subsets showed that the genetic testing harm ‘insurance discrimination’ contributed significantly to parents’ attitude. This implies that confidentiality in genetic testing for ASD is important. The concern about insurance is unexpected in Norway where the health care system is public and any kind of discrimination on the basis of genetic constitution is prohibited by law [26]. The genetic testing variable ‘understand ASD’ also contributed significantly to this attitude, and relatively more so than the practical benefits and harms, which may indicate that knowledge of the cause of the condition is of primary importance for the parents, perhaps as a sense of relief from uncertainty.

Another main finding was that only 41.1% of the respondents agreed that it is important to inform as many as possible in the family about genetic risk of ASD. This supports hypothesis #2. Parents in favour of clinical genetic testing were indifferent, not positive, to extensive intra-familial disclosure, which may underscore the need for confidentiality even within the family. This seems in accordance with the duty of confidentiality of professionals towards their patients [22]. In the familial sphere this attitude seems to differ from a previously documented altruism towards contributing to genetic research in the current sample [29] and may also be seen to conflict with the focus on solidarity in communal models of ethics [33]. Agreement to extensive intra-familial disclosure was significantly stronger for those with children with increased disease severity. This may indicate inadequate knowledge of inheritance patterns and underscore the importance of genetic counseling as higher heritability is associated with milder ASD subtypes [3, 34]. It may also be explained by a perception of burden of which symptom severity is a predictor [35].

In support of the first part of our hypothesis #3 we found that the majority of parents (58.0 %) agree that everyone has an obligation to know as much as possible relevant for future health of oneself and one’s children. This was positively associated with the testing variables (“understand ASD”, “family planning” and “improved planning of interventions and facilitations” etc.) and negatively associated with the variable “family conflict”. This may indicate a focus on their child’s best interests rather than on their own, in line with a recent finding among parents of paediatric neurology patients [36]. Parents’ attitudes may in some cases come in conflict with the child’s future autonomy and “right not to know” although concern for their children’s best interests may indeed facilitate development of autonomy in other cases [37, 38].

We found that half of the sample (51.7%) agreed that it is important to have a “right not to know”, which did not support our hypothesis #4. This result is not in accordance with previous results [25]. A “right not to know” seems explicitly to be connected to informational privacy [39]. In the perspective of practical everyday coping, respect for individual privacy may relate to spatial privacy directed to the individual’s sense of self [40] and individual preferences may be a topic for genetic counseling rather than for legislation. A practical perspective of genetic testing with counseling and support may explain the relative infrequent interest in a “right” not to know. A “right not to know” was associated with “insurance discrimination”, which may be less relevant in countries with public health insurance. It was also related to instigating “family conflict” and “increased concern” for future health and development, both important aspects of genetic counseling.

The attitudes documented here are from parent members of an advocacy organization. Advocacy communities tend to focus on talents and advantageous traits and that the cognitive styles characteristic of ASD may contribute productively to science and society [41, 42]. If ASD is not considered a disease, but rather a valuable trait, attitudes towards genetic testing and genetic information may be affected. The terminology of risk used in medical genetics clinic and genetics research may be unfortunate since it may downplay positive traits. Furthermore, our use of the “disease severity” diagnostic/symptom criteria from international research terminology [43] may not necessary reflect challenges experienced by individuals on the autism spectrum and their families [44]. In the current paper and in the questionnaire, we have used standard international terminology, while we recommend more neutral terms in line with preferences of the communities, such as condition rather than disorder.
Table 3. Independent variables for interest in sharing genetic risk information and knowing about future health.

| Variable                | Disagree Entirely (1) | Disagree Partly (2) | Neither (3) | Agree Partly (4) | Agree Entirely (5) | Don't know / no opinion | n    | Statement                                                                 |
|-------------------------|-----------------------|---------------------|-------------|------------------|-------------------|------------------------|------|---------------------------------------------------------------------------|
| Treatment relevant      | 17.83%                | 9.55%               | 9.84%       | 20.67%           | 32.41%            | 9.69%                  | 1413 | "I would take a genetic test only if it had direct treatment consequences for me or my children." |
| Cause explained         | 7.59%                 | 4.15%               | 5.56%       | 20.04%           | 56.33%            | 6.33%                  | 1422 | "I would take a genetic test if it could help explain the cause of my own or my children's condition." |
| Future treatment        | 12.89%                | 7.18%               | 8.17%       | 26.90%           | 36.83%            | 8.03%                  | 1420 | "I would take a genetic test only if it could contribute to better treatment in the future; not necessarily for my own children." |
| Understand ASD          | 4.91%                 | 2.39%               | 4.56%       | 20.63%           | 62.95%            | 4.57%                  | 1425 | "I would take a genetic test if this would contribute to a better understanding of what ASD really is." |
| Prevent recurrence      | 30.66%                | 7.82%               | 10.08%      | 11.42%           | 28.54%            | 11.49%                 | 1419 | "I would take a genetic test if it provided an opportunity to prevent me from having more children with ASD." |
| Family planning         | 37.90%                | 15.46%              | 15.38%      | 11.93%           | 12.14%            | 7.20%                  | 1417 | "Genetic testing is important for family planning." |
| Improve planning        | 5.79%                 | 3.91%               | 7.82%       | 26.00%           | 48.81%            | 7.68%                  | 1381 | "An early diagnosis based on genetic testing will improve the opportunities for planning good interventions and facilitations." |
| Social construction     | 30.34%                | 16.87%              | 11.44%      | 16.36%           | 9.27%             | 15.72%                 | 1381 | "Difficulties due to ASD are mainly socially constructed. Genetic testing will therefore in any case have minimal consequences for interventions and facilitations." |
| Insurance discrimination| 5.48%                 | 2.74%               | 7.35%       | 20.84%           | 45.93%            | 17.66%                 | 1387 | "A genetic test that shows the risk of developing ASD will lead to discrimination from insurance companies." |
| Increased concern       | 14.16%                | 10.40%              | 11.42%      | 31.79%           | 24.35%            | 7.88%                  | 1384 | "Early diagnosis based on genetic testing will increase parents’ concern for the child's future health and development." |
| Family conflict         | 10.37%                | 7.25%               | 18.93%      | 29.30%           | 19.65%            | 14.51%                 | 1379 | "Genetic testing can lead to family conflicts." |

*5-point agreement scale. Scenario: "Currently no test can predict ASD. Imagine there was a genetic test that could determine risk of ASD. To what extent do you agree or disagree with the following statements?" All rows add to 100 %.
Table 4. A Stepwise analyses: “decide who to inform,” “inform as many as possible,” “obligation to know” and “right not to know.” B Reports of stepwise analyses and best subset models: “decide who to inform,” “inform as many as possible,” “obligation to know” and “right not to know.”

### A

| Variable                      | p values | p values |
|-------------------------------|----------|----------|
|                               | 0        | 1        | 2        | 3        | 4        | 5        | 6        | 7        | r        | 0        | 1        | 2        | 3        | 4        |
| Treatment relevant            | 0.136    | <0.001   | 0.003    | 0.016    | 0.017    | 0.032    | 0.043    |          |          | 0.075    | 0.011    | 0.005    | ~0.169   | 0.230    | 0.422    |
| Explain cause                 | 0.141    | <0.001   |          |          |          |          |          |          |          | <0.001   | 0.001    | 0.001    | 0.010    |          |          |
| Future treatment              | 0.111    | <0.001   |          |          |          |          |          |          |          | <0.001   | 0.001    | ~0.095   | 0.279    | 0.566    |          |
| Understand ASD               | 0.208    | <0.001   |          |          |          |          |          |          |          | <0.001   | 0.000    | 0.014    | ~0.114   | 0.704    |          |
| Recurrence prevention         | 0.009    | 0.772    | 0.234    | 0.486    | 0.930    | 0.913    | 0.478    | 0.303    | 0.331    | 0.415    | <0.001   | 0.000    | <0.001   |          |          |
| Family planning               | ~0.071   | 0.015    | ~0.157   | 0.004    | 0.013    | 0.022    | 0.003    |          |          |          |          |          |          |          |          |
| Improve planning              | 0.173    | <0.001   | 0.008    | 0.002    |          |          |          |          |          |          |          |          |          |          |          |
| Social construction           | 0.162    | <0.001   |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Insurance discrimination      | 0.270    | <0.001   |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Increased concern             | 0.144    | <0.001   | 0.001    | 0.002    |          |          |          |          |          |          |          |          |          |          |          |
| Family conflict               | 0.177    | <0.001   | 0.001    | 0.001    |          |          |          |          |          |          |          |          |          |          |          |
| Adjusted R²                   |          |          |          |          |          |          |          |          |          |          |          |          |          |          |          |

### B

| Variable                      | p values | p values |
|-------------------------------|----------|----------|
|                               | 0        | 1        | 2        | 3        | 4        | 5        | 6        |          |          |          | 0        | 1        | 2        | 3        | 4        |
| Treatment relevant            | 0.120    | <0.001   | 0.010    | 0.003    | 0.016    | 0.010    |          | ~0.143   | 0.138    | 0.078    | 0.007    | 0.019    | 0.040    | ~0.070   | 0.306    |
| Explain cause                 | 0.296    | <0.001   | <0.001   | <0.001   | 0.042    | ~0.076   | 0.097    | 0.148    |          | ~0.035   | 0.222    | 0.794    | 0.664    | 0.665    | 0.287    |
| Future treatment              | 0.200    | <0.001   | <0.001   |          | 0.004    | 0.002    |          |          |          |          | 0.009    | 0.018    | 0.019    | 0.038    |          |
| Understand ASD               | 0.299    | <0.001   | <0.001   | <0.001   |          |          |          |          |          |          | 0.882    | 0.798    | 0.843    | 0.824    | 0.228    |
| Recurrence prevention         | 0.268    | <0.001   | <0.001   | 0.004    | 0.034    | 0.027    | 0.039    |          |          |          | 0.290    | 0.561    | 0.855    | 0.783    | 0.541    |
| Family planning               | 0.286    | <0.001   | <0.001   |          |          |          |          |          |          |          |          |          |          |          |          |
| Improve planning              | 0.340    | <0.001   |          |          |          |          |          |          |          |          | 0.077    | 0.426    | 0.175    | 0.214    | 0.093    |
| Social construction           | ~0.035   | 0.250    | 0.967    | 0.451    | 0.335    | 0.143    | 0.310    | 0.209    | 0.085    |          | 0.005    | ~0.085   | 0.248    | 0.373    | 0.485    |
| Insurance discrimination      | ~0.037   | 0.223    | 0.029    | ~0.190   | 0.095    | 0.588    | 0.672    | 0.806    | 0.200    |          |          |          |          |          |          |
| Increased concern             | ~0.110   | <0.001   | 0.007    | 0.012    | 0.007    | ~0.458   | 0.297    | 0.266    | 0.209    |          | ~0.001   |          |          |          |          |
| Family conflict               | ~0.167   | <0.001   | <0.001   | <0.001   |          |          |          |          |          |          |          |          |          |          |          |
| Adjusted R²                   | 0.115    | 0.157    | 0.177    | 0.189    | 0.196    | 0.198    |          |          |          | 0.054    | 0.073    | 0.082    | 0.085    |          |          |
| Step | Variable added | Variable | Coef. | p    | 95 % CI | RVI |
|------|----------------|----------|-------|------|---------|-----|
| 1    | Insurance discrimination | Insurance discrimination | 0.172 | <0.001 | 0.115–0.229 | 0.274 |
| 2    | Understand ASD | Understand ASD | 0.176 | <0.001 | 0.110–0.243 | 0.213 |
| 3    | Social construction | Improve planning | 0.131 | <0.001 | 0.072–019.0 | 0.150 |
| 4    | Family conflict | Social construction | 0.100 | <0.001 | 0.055–0.146 | 0.145 |
| 5    | Improve planning | Family planning | −0.071 | 0.001 | −0.114 to −0.027 | 0.080 |
| 6    | Family planning | Family conflict | 0.085 | 0.004 | 0.026–0.143 | 0.066 |
| 7    | Treatment relevant | Treatment relevant | 0.045 | 0.030 | 0.004–0.086 | 0.037 |

Others considered: Recurrence prevention.

* Auto data preparation (trim outliers, replace missing values), selection criterion: AICC; Adjusted $R^2 = 0.143$; RVI relative variable importance

| Step | Variable added | Variable | Coef. | p    | 95 % CI | RVI |
|------|----------------|----------|-------|------|---------|-----|
| 1    | Improve planning | Improve planning | 0.224 | <0.001 | 0.152–0.296 | 0.379 |
| 2    | Family planning | Family planning | 0.151 | <0.001 | 0.092–0.210 | 0.255 |
| 3    | Understand ASD | Understand ASD | 0.139 | 0.003 | 0.047–0.232 | 0.088 |
| 4    | Family conflict | Family conflict | −0.102 | 0.003 | −0.170 to −0.034 | 0.087 |
| 5    | Future treatment | Future treatment | 0.077 | 0.011 | 0.017–0.137 | 0.065 |
| 6    | Recurrence prevention | Recurrence prevention | 0.058 | 0.031 | 0.005–0.110 | 0.047 |

Others considered: Social construction.

* Auto data preparation (trim outliers, replace missing values), selection criterion: AICC; Adjusted $R^2 = 0.190$; RVI relative variable importance

---

| Step | Variable added | Variable | Coef. | p    | 95 % CI | RVI |
|------|----------------|----------|-------|------|---------|-----|
| 1    | Family planning | Improve planning | 0.336 | <0.001 | 0.269–0.403 | 0.451 |
| 2    | Family planning | Family planning | 0.255 | <0.001 | 0.197–0.313 | 0.349 |
| 3    | Recurrence prevention | Recurrence prevention | 0.143 | <0.001 | 0.092–0.194 | 0.140 |
| 4    | Explain cause | Explain cause | 0.102 | 0.002 | 0.038–0.165 | 0.045 |

* Auto data preparation (trim outliers, replace missing values), selection criterion: AICC; Adjusted $R^2 = 0.305$; RVI relative variable importance

---

Table 4 continued

Report of “decide who to inform” stepwise analysis

Best subset* model of “decide who to inform”

Report of “inform as many as possible” stepwise analysis

Best subset* model of “inform as many as possible”

Report of “obligation to know” stepwise analysis

Best subset* model of “obligation to know”

Report of “right not to know” stepwise analysis

Best subset* model of “right not to know”

---

Pearson correlation coefficients; > variable selected for entry; ~ identification of close alternative; ? weak close alternative (A close alternative is a variable originally significant, later non-significant after selection of some other variable); [] Variable in model; Selection criteria: $p < 0.05$ to enter, $p > 0.10$ to remove. $P$ values of all models: <.001.
The current study provides new empirical knowledge about attitudes in ASD families toward principles regulating generation and dissemination of genetic risk information. Despite its large size, our sample may not be fully representative of attitudes of ASD parents as it was recruited from an advocacy group. Other limitations are lack of comprehensive demographic information, little information about disease severity and lack of information of other children in the family with an ASD diagnosis or psychiatric conditions, which may have impacted the parents’ attitudes. It is also a limitation that the questions were adapted from a questionnaire about malignant melanoma which, although they were general, may be less suitable for ASD. The data was collected in 2014, but the changes in clinical genetics mainly involve new technical equipment, while clinical genetics services are still underutilized in ASD [45], making our findings relevant to the current state of ASD clinical genetics.

In conclusion, these findings illustrate the complexity of the attitudes towards genetic testing in ASD and underscore the need for comprehensive genetic counseling. The results support current trends advocating to move away from non-directiveness and promote a proactive approach that involve recommendations to provide contextual information upon delivery of ASD genetic information, little information about disease severity and lack of attitudes in ASD parents as it was recruited from an advocacy group. Furthermore, the findings support current counseling practices which addresses physical, societal, material and emotional aspects of individual families [47]. Our findings also underscore the need to provide contextual information upon delivery of ASD genetic risk information, in line with findings in general psychiatry [48]. Replication in independent samples is warranted before ethical guidelines relevant to modern genetic testing and counseling in ASD are revised.

DATA AVAILABILITY
The datasets generated during and/or analyzed during the current study are available in the Open Science Framework repository, https://osf.io/zs3mr/

REFERENCES
1. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychological Med. 2015;45:601–13.
2. Sandin S, Lichtenstein P, Kuja-Halkola R, Hultman C, Larsson H, Reichenberg A. Modabbernia A, Scherer SW, Bellgrove MA, Hawi Z Environmental exposures associated with autism. The heritability of autism spectrum disorder. JAMA. 2017;318:1182–4.
3. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:207–18.
4. Sandin S, Lichtenstein P, Kuja-Halkola R, Hultman C, Larsson H, Reichenberg A. Environmental factors for autism: a guide for clinicians. Curr Psychiatry Rev. 2012;15:593–8.
5. Schaefer G. Clinical genetic aspects of autism spectrum disorders. Int J Mol Sci. 2016;17:180–14.
6. Bräström R, Kasparian NA, Affleck P, Tibben A, Chang Y-m, Azizi E, et al. Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. Eur J Cancer (Oxford, England: 1990). 2012;48:3052–62.
7. Thapar A, Rutter M Genetic advances in autism. J Autism Dev Disord. 2020; 1–12. https://doi.org/10.1007/s10803-020-04685-z.
8. Kitzman R. “I am my genes”: Questions of identity among individuals confronting genetic disease. Genet Med. 2009;11:880–9.
9. Pilk AC, Dalvie S, de Vries J, Martin AR, Stein DJ. Potential use of clinical polygenic risk scores in psychiatry—ethical implications and communicating high-pen genotype risk. Philos Ethics Humanities Med. 2019;14:748.
10. Selkirk CG, McCarthy Veach P, Lian F, Schimmenti L, LeRoy BS. Parents’ perceptions of autism spectrum disorder etiology and recurrence risk and effects of their perceptions on family planning: recommendations for genetic counselors. J Genet Counseling. 2009;18:507–19.
11. Rev L, Mackert M, Bonevac D. A systematic review of literature about the genetic testing of adolescents. J Specialists Pediatr Nurs. 2009;14:284–94.
12. Hens K, Peeters H, Diericks K. Genetic testing and counseling in the case of an autism diagnosis: a caregivers perspective. Eur J Med Genet. 2016;59:1–7.
13. Lim Q, McGill BC, Quinn VF, Tucker KM, Mizrahi D, Patenaude AF, et al. Parents’ attitudes toward genetic testing of children for health conditions: a systematic review. Clin Genet. 2017;92:569–78.
14. Rev L, Kaur M, McMillan A, Mackert M, Bonevac D. Systematic review of psychosocial benefits and harms of genetic testing. Issues Ment Health Nurs. 2017;31:1–16.
15. Marchant GE, Robert JS Genetic testing for autism predisposition: Ethical Legal Social Challenges. Hous J Health L & Pol'y. 2009.
16. Chen LS, Xu L, Huang T-Y, Dhar SU. Autism genetic testing: a qualitative study of awareness, attitudes and experiences among parents of children with autism spectrum disorders. Genet Med. 2013;15:274–81.
17. Erik P, Paul SA. On what we have learned and still need to learn about the psychosocial impacts of genetic testing. Hastings Cent Rep. 2019;49:52–59.
18. Wade CH. What is the psychosocial impact of providing genetic and genomic health information to individuals? An overview of systematic reviews. Hastings Cent Rep. 2019;49:588–596.
19. Andorno R. The right not to know: an autonomy based approach? J Med Ethics. 2004;30:435–9. - discussion 9-40
20. Andorno R. Do our moral judgments need to be guided by principles? Camb Q Health Ethics. 2012;21:457–65.
21. Strohmaier J, Witt SH, Frank J, Lemme N, Flatau L, Streit F, et al. Attitudes toward the right to autonomous decision-making in psychiatric genetic testing: Controversial and context-dependent. Am J Med Genet Part B: Neuropsychiatr Genet. 2019;22:401–11.
22. Laëgsgaard MM, Mors O. Psychiatric genetic testing: attitudes and intentions among future users and providers. Am J Med Genet Part B: Neuropsychiatr Genet. 2008;147:375–84.
23. Johannessen J, Nærlund T, Hope S, Torske T, Hayland A, Strohmaier J, et al. Parents’ Attitudes toward Clinical Genetic Testing for Autism Spectrum Disorder —Data from a Norwegian Sample. Int J Mol Sci. 2017;18:1078–14.
24. Wolff K, Nordin K, Brun W, Berglund G, Kvale G. Affective and cognitive attitudes, uncertainty avoidance and intention to obtain genetic testing: an extension of the theory of planned behaviour. Psychol Health. 2011;26:1143–55.
25. Oien R, Nordahl-Hansen A Norway and Autism. Encyclopaedia of autism spectrum disorders. 2017. p. 1-6.
26. Johannessen J, Nærlund T, Blass C, Rietschel M, Strohmaier J, Gjekv E, et al. Parents’ attitudes toward genetic research in autism spectrum disorder. Psychiatr Genet. 2016;26:74–80.
27. Carillo J, Perla RJ. Ten common misunderstandings, misconceptions, persistent myths and urban legends about likert scales and likert response formats and their antedotes. J Soc Sci. 2007;3:106–16.
28. Hauck WW, Mike R. A proposal for examining and reporting stepwise regressions. Stat Med. 1991;10:5.
29. Yang H. The case for being automatic: introducing the automatic linear modeling (LINEAR) procedure in SPSS statistics. Mult Linear Regres Viewp. 2013;29:10.
30. Borotkoti L, Widdows H. The right not to know: the case of psychiatric disorders. J Med Ethics. 2011;37:873–6.
31. Robinson EB, Samocha KE, Kosmicki JA, McGrath L, Neale BM, Perlis RH, et al. Autism spectrum disorder severity reflects the average contribution of de novo and familial influences. Proc Natl Acad Sci USA. 2014;111:15161–S.
32. Picardi A, Gigantesco A, Tarolla E, Stoppioni V, Cerbo R, Cremonte M, et al. Parents’ attitudes toward genetic research in autism spectrum disorder etiology and recurrence risk and effects of their perceptions on family planning: recommendations for genetic counselors. J Genet Counseling. 2009;18:507–19.
33. Feinberg J The Child’s Right to an Open Future (1980). In: Feinberg J, editor. Freedom and Fulfillment: Philosophical Essays: Princeton University Press; 1992. p. 76-97.
38. Robertson S, Savulescu J. Is there a case in favour of predictive genetic testing in young children? Bioethics 2001;15:26–49.
39. Laurie. In Defence of Ignorance: Genetic Information and the Right not to Know. Eur J Health Law. 1999;6:119-32.
40. Laurie G, Harmon S, Dove E Mason and McCall Smith’s Law and Medical Ethics. 2019.
41. Singh JS Multiple Autisms. Spectrums of Advocacy and Genomic Science: University of Minnesota Press; 2015.
42. Happe F, Vital P. What aspects of autism predispose to talent? Philos Trans R Soc Lond B Biol Sci. 2009;364:1369–75.
43. Mehlng MT, Tassé MJ. Severity of autism spectrum disorders: current conceptualization, and transition to DSM-5. J Autism Developmental Disorder. 2016;46:2000–16.
44. Russell G, Kapp SK, Elliott D, Elphick C, Gwernan-Jones R, Owens C. Mapping the autistic advantage from the accounts of adults diagnosed with autism: a qualitative study. Autism Adulthood. 2019;1:124–33.
45. Dragojlovic N, Kopac N, Borle K, Tandun R, Salmasi S, Ellis U, et al. Utilization and uptake of clinical genetics services in high-income countries: a scoping review. Health Policy. 2021;125:877–87.
46. Schupmann W, Jamal L, Berkman BE. Re-examining the ethics of genetic counselling in the genomic era. J Bioeth Inq. 2020;17:325–35.
47. Lunde Å Tensions in practice, knowledge and regulation: genetic counseling in Norway [PhD]. Bergen, Norway: University of Bergen; 2014.
48. Driver MN, Kuo SI, Dick DM. Genetic feedback for psychiatric conditions: where are we now and where are we going. Am J Med Genet B Neuropsychiatr Genet. 2020;183:423–32.

ACKNOWLEDGEMENTS
We are thankful to the participants in the study and to Ida Elken Sønderby for valuable comments, suggestions and proof-reading. The project was supported by the Research Council of Norway (213694, 223273, 248980) and EEA Grant 2014–2021 (6/2019), and the KG Jebsen Stiftelsen (# SKGJ-MED-021).

COMPETING INTERESTS
The authors declare no competing interests.

ETHICAL APPROVAL
The study did not require IRB approval because data was collected anonymously.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Jarle Johannessen.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021